136 related articles for article (PubMed ID: 8666519)
1. Therapy of hepadnavirus infection using antisense oligonucleotides.
Offensperger WB; Blum HE; Gerok W
Intervirology; 1995; 38(1-2):113-9. PubMed ID: 8666519
[TBL] [Abstract][Full Text] [Related]
2. Antisense therapy of hepatitis B virus infection.
Offensperger WB; Offensperger S; Blum HE
Mol Biotechnol; 1998 Apr; 9(2):161-70. PubMed ID: 9658393
[TBL] [Abstract][Full Text] [Related]
3. Molecular therapeutic strategies in hepatitis B virus infection.
Offensperger WB; Blum HE; Gerok W
Clin Investig; 1994 Oct; 72(10):737-41. PubMed ID: 7865975
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo.
Offensperger WB; Offensperger S; Keppler-Hafkemeyer A; Hafkemeyer P; Blum HE
Antivir Ther; 1996 Aug; 1(3):141-6. PubMed ID: 11322247
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver.
Robaczewska M; Guerret S; Remy JS; Chemin I; Offensperger WB; Chevallier M; Behr JP; Podhajska AJ; Blum HE; Trepo C; Cova L
Gene Ther; 2001 Jun; 8(11):874-81. PubMed ID: 11423935
[TBL] [Abstract][Full Text] [Related]
7. [Inhibition of duck hepatitis B virus DNA replication by antisense phosphorothioate oligodeoxynucleotides in vitro and in vivo].
Dong B; Shao XW; Tao PZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Mar; 17(1):25-7. PubMed ID: 12870012
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
9. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
Pei Y; Wang C; Yan SF; Liu G
J Med Chem; 2017 Aug; 60(15):6461-6479. PubMed ID: 28383274
[TBL] [Abstract][Full Text] [Related]
10. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
Saade F; Buronfosse T; Guerret S; Pradat P; Chevallier M; Zoulim F; Jamard C; Cova L
J Viral Hepat; 2013 Apr; 20(4):e56-65. PubMed ID: 23490390
[TBL] [Abstract][Full Text] [Related]
11. Developments in Cell-Penetrating Peptides as Antiviral Agents and as Vehicles for Delivery of Peptide Nucleic Acid Targeting Hepadnaviral Replication Pathway.
Ndeboko B; Hantz O; Lemamy GJ; Cova L
Biomolecules; 2018 Jul; 8(3):. PubMed ID: 30013006
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L.
Liu S; Wei W; Shi K; Cao X; Zhou M; Liu Z
J Ethnopharmacol; 2014 Sep; 155(2):1061-7. PubMed ID: 25009077
[TBL] [Abstract][Full Text] [Related]
14. Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo.
Bingfa X; Qinglin F; Hui H; Canjun W; Wei W; Lihua S
Pharmacology; 2009; 83(6):323-32. PubMed ID: 19407486
[TBL] [Abstract][Full Text] [Related]
15. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides.
Moriya K; Matsukura M; Kurokawa K; Koike K
Biochem Biophys Res Commun; 1996 Jan; 218(1):217-23. PubMed ID: 8573134
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.
Mason WS; Cullen J; Saputelli J; Wu TT; Liu C; London WT; Lustbader E; Schaffer P; O'Connell AP; Fourel I
Hepatology; 1994 Feb; 19(2):398-411. PubMed ID: 8294097
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L.
Li J; Huang H; Feng M; Zhou W; Shi X; Zhou P
Antiviral Res; 2008 Aug; 79(2):114-20. PubMed ID: 18423640
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica.
Han YQ; Huang ZM; Yang XB; Liu HZ; Wu GX
J Ethnopharmacol; 2008 Jun; 118(1):148-53. PubMed ID: 18495393
[TBL] [Abstract][Full Text] [Related]
19. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
20. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
